- 學位論文
肝癌併肝門靜脈栓塞病患進行放射線治療之預後相關因子分析
Analysis of the prognostic and related factors in hepatocellular carcinoma patients with portal vein thrombosis after radiotherapy
摘要
背景 肝癌在台灣是排名第二常見的惡性腫瘤。當肝癌合併肝門靜脈或下腔靜脈阻塞時，目前為止治療效果不好，預後差。對於上述情形，放射線是主要的治療方式。腫瘤於放射治療時需增加安全距離，以防止正常組織在放射治療時受到過多的傷害。本研究的目的主要在探討治療相關的預後因子，如何執行有品質與安全的放射線治療。 方法 選擇分析肝癌合併門靜脈阻塞病人資料，包含人口基本資料，於治療前後的血液生化值、腫瘤相關特性，放射治療方式。主要觀察的為整體存活時間。上述可能的預後因子，須經過單變相與多變項分析。計算計劃靶體積，以評估進行肝腫瘤放射治療時需增加多少安全距離，能符合國際上對於肝臟放射耐受之安全劑量範圍。藉由螺旋光子刀，於腹腔腫瘤放射治療時，記錄肝臟不同方向的每日誤差。 結果 自2009年4月至2012年10月，共10位病人有肝癌合併肝門靜脈阻塞，並接受放射線治療。整體平均存活時間，有超過一半治療反應的約14.1個月，無反應或變差的，只有4.3個月（p=0.001）。治療前的不好預後因子包含嚴重的期別、年紀大於60歲、B型肝炎陽性、高AST數值與差的child-pugh classification。治療後的不好預後因子包含高膽紅素值、低白蛋白、高AST數值（p <0.05）。可視腫瘤需增加距離成為計劃靶體積，X（左/右），Y（上/下），Z（進/出）最大值分別為 4公厘、8公厘、8公厘。每日隨機誤差X、Y、Z平均值分別為3.01公厘、2.8公厘、3.14公厘。 結論 研究結果有助於了解對於肝癌合併肝門靜脈栓塞病人，會影響生存時間的預後因子。放射線治療對於肝門靜脈治療是有效的。須小心增加適當且安全的距離，來克服每日移動的誤差。
並列摘要
BACKGROUND Hepatocellular carcinoma（HCC）is the second most common malignancies in Taiwan. Patients with HCC who had portal vein or inferior vena cava tumor thrombosis （PVT or IVCT） are considered as poorer treatment outcomes and radiotherapy （RT） is main treatment for those patients. In cancer radiotherapy, safety margin should be added around gross tumor volume （GTV） to overcome uncertainties in planning or treatment delivery. To clarify prognostic factors, safety and quality of RT in those patients is important for further therapeutic design. METHODS Patients with HCC who had PVT or IVCT and received RT were enrolled in this study. Demographic variables, laboratory values, tumor characteristics, and RT modalities were determined before and post RT. The primary end point was overall survival. Predicted factors of survival were identified using the univariate and multivariate analysis. Calculation of planning target volume （PTV） was used to evaluate the safety margin. The imaging records of TomoTherapy in treatment of abdomen or pelvic tumors were used to evaluate daily different directions motion of liver. RESULTS Ten patients with HCC who had PVT or IVCT received RT between April 2009 and October 2012 were enrolled. Overall median survival in partial response group was 14.1 months versus 4.3 months in stable or progress group （p =0.001）. Pretreatment unfavorable predictors were advanced stage, old age, positive of HBsAg, higher AST（aspartate aminotransferase） and poorer Child–Pugh classification. Post treatment unfavorable predictors were higher total biliribum, lower albumin, higher AST （95% confidence interval, p <0.05）. GTV safety maximal margin at different directions of X（right/left）, Y（up/down）, Z（in/out） were 4mm, 8mm and 8mm, respectively. Daily random motion of abdomen or pelvic tumor treatment, mean value at different directions of X, Y and Z were 3.01mm, 2.8mm and 3.14mm, respectively. Conclusions The results will help in understanding the potential factors that influence survival for patients with HCC after RT. Radiotherapy is effective for PVT or IVCT. Careful add adequate margin could safely overcome daily motions.
參考文獻
延伸閱讀
- Yeh, S. A., Chen, Y. S., Perng, D. S., & Chang, L. (2015). 放射線治療於治療肝細胞癌合併下腔靜脈腫瘤栓塞之角色. 放射治療與腫瘤學, 22(4), 267-274. https://doi.org/10.6316/TRO/201522(4)267
- 張靜宜（2008）。肝癌病人放射線累積劑量、細胞激素濃度與症狀嚴重度相關性之縱貫分析〔碩士論文，臺北醫學大學〕。華藝線上圖書館。https://doi.org/10.6831/TMU.2008.00108
- 陳怡君（2017）。肝癌患者接受射頻燒灼術或經導管動脈(化學)栓塞之廣效性抗生素使用研究〔碩士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-2208201720305900
- 王湘茹（2009）。肝癌病患接受肝切除術與經導管肝動脈化學栓塞之健康相關生活品質之探討〔碩士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-0408200921472900
- Hsu, W. C., Wang, P. M., Ying, K. S., Chao, C. J., Huang, J. C., & Lin, G. D. (2002). Preliminary Results of Three-dimensional Conformal Radiotherapy for Hepatocellular Carcinoma with Portal Vein Thrombosis. 中華放射線醫學雜誌, 27(2), 59-66. https://www.airitilibrary.com/Article/Detail?DocID=10188940-200204-27-2-59-66-a